Healthcare Weekly Jamaica: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Weekly Jamaica.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on February 2, 2026

Feb. 2, 2026

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

GlobeNewswire

Feb. 2, 2026

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

GlobeNewswire

Feb. 2, 2026

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

GlobeNewswire

Feb. 2, 2026

Global Pharmaceutical Filtration Market Projected to Achieve 11.1% CAGR Through 2030

GlobeNewswire

Feb. 2, 2026

Sago Health Announces Rebrand to TriVoca Health

GlobeNewswire

Feb. 2, 2026

Groundbreaking therapy for advanced heart failure

GlobeNewswire

Feb. 2, 2026

Bahnbrechende Therapie für fortgeschrittene Herzinsuffizienz

GlobeNewswire

Feb. 2, 2026

Agomab Announces Launch of Initial Public Offering

GlobeNewswire

Feb. 2, 2026

Iridex Announces Plans to Relocate Headquarters

GlobeNewswire

Feb. 2, 2026

Guidelight Expands to California with Opening of Los Angeles Clinic

GlobeNewswire

Feb. 2, 2026

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

GlobeNewswire

Feb. 2, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

GlobeNewswire

Feb. 2, 2026

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

GlobeNewswire

Feb. 2, 2026

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

GlobeNewswire

Feb. 2, 2026

Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging

GlobeNewswire

Feb. 2, 2026

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

GlobeNewswire

Feb. 2, 2026

BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism

GlobeNewswire

Feb. 2, 2026

How Consumers Evaluate Mullein Extract Supplements and Drops in 2026: New Research from NUTRAHARMONY

GlobeNewswire

Feb. 2, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

GlobeNewswire

Feb. 2, 2026

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

GlobeNewswire